Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
1.28 M
Value Traded
31.88 M
Short % Float
-
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
-
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
-
Float Shares
-
Insiders
-
Institutions
-
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
WWB Catalyst Timeline
Dated clinical, regulatory and corporate events for Windward Bio Group AG
Past FDA Catalysts and PDUFA Decisions
How WWB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every WWB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in WWB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in WWB for Q2 2026. | ||||
Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How WWB ranks across every disease it competes in
Competitive Position is a premium feature
See how WWB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialWWB News
-WWB
Nov 14, 2026Innovative Immunology Biotech Windward Bio Lists on Nasdaq
Windward Bio successfully listed on Nasdaq on November 13, 2026, pricing its IPO at $17.00 per share. Shares surged to $28.50 on the first day, resulting in a market cap of about $1.69 billion. The company focuses on developing biologic therapies for chronic inflammatory diseases, with lead programs in severe asthma and COPD.
Read more →-WWB
Nov 12, 2026Windward Bio Announces Pricing of Initial Public Offering
Windward Bio Group AG announced its initial public offering, pricing 10,294,117 shares at $17.00 each. The offering is expected to raise $225.0 million, with a concurrent private placement to Sanofi for $50.0 million. Trading on the Nasdaq is set to commence on November 13, 2026, with the offering closing on November 16, 2026.
Read more →About Windward Bio Group AG
BIOPHARMAWATCH ELITE
Trade the next WWB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime